PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Khan, Muhammad [1 ]
机构：
[1] DOW Univ Hosp, Karachi, Pakistan
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
MP077
引用
收藏
页码：295 / 295
页数：1
相关论文
共 50 条
  • [21] Incidence and Risk Factors for Leukopenia in Kidney Transplant Recipients Receiving Valganciclovir for Cytomegalovirus Prophylaxis.
    Liang, C.
    Famure, O.
    Li, Y.
    Kim, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 319 - 319
  • [22] Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Brady, R. L.
    Green, K.
    Frei, C.
    Maxwell, P.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (02) : 106 - 111
  • [23] Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy versus prophylaxis
    Zamora, Danniel
    Dasgupta, Sayan
    Stevens-Ayers, Terry
    Edmison, Bradley
    Winston, Drew J.
    Razonable, Raymund R.
    Mehta, Aneesh K.
    Lyon, G. Marshall
    Boeckh, Michael
    Singh, Nina
    Koelle, David M.
    Limaye, Ajit P.
    JCI INSIGHT, 2024, 9 (18)
  • [24] Preemptive Therapy Versus Valgancyclovir Prophylaxis in Cytomegalovirus-positive Kidney Transplant Recipients Receiving Antithymocyte Globulin Induction
    Couzi, L.
    Helou, S.
    Bachelet, T.
    Martin, S.
    Moreau, K.
    Morel, D.
    Lafon, M. E.
    Garrigue, I.
    Merville, P.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (09) : 2809 - 2813
  • [25] Abolition of cytomegalovirus disease with aggressive prophylaxis and preemptive therapy in mismatched lung transplant recipients
    Hopkins, P. M.
    Kermeen, F.
    Dunning, J.
    McNeil, K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (02): : S174 - S174
  • [26] Preemptive therapy of cytomegalovirus disease in pediatric transplant recipients
    Green, M
    Michaels, M
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (09) : 875 - 877
  • [27] Pre-Emptive Therapy Versus Valganciclovir Prophylaxis for De Novo Cytomegalovirus (CMV)-Seropositive Kidney-Transplant Recipients
    Weclawiak, Hugo
    Kamar, Nassim
    Mengelle, Catherine
    Esposito, Laure
    Izopet, Jacques
    Rostaing, Lionel
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 : 385 - 385
  • [28] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
  • [29] Standard-versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients.
    Wilson, N.
    Sulejmani, N.
    Jantz, A.
    Patel, A.
    Summers, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 532 - 532
  • [30] Oral valganciclovir prophylaxis in kidney transplant recipients
    Manuel, O.
    Fellay, J.
    Venetz, J-P.
    Sturzenegger, N.
    Meylan, R.
    Pascual, M.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 : S16 - S16
12345